Latest Research Evaluating VASCEPA/VAZKEPA (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023 - Seite 2

“This latest research reaffirms Amarin's commitment to advancing cardiovascular care and highlights the potential benefits of VASCEPA/VAZKEPA in improving the health and well-being of patients at increased risk of cardiovascular events,” concluded Abadir.

Featured Amarin-supported abstracts to be presented at AHA Scientific Sessions 2023 include:

Oral Presentation

• Effectiveness of Icosapent Ethyl on First and Total Cardiovascular Events in the Metabolic Syndrome: REDUCE-IT MetSyn ​
  

Michael Miller, Deepak L. Bhatt, Eliot A. Brinton, Terry A Jacobson et al...

– Available November 12th, 9-9:10 am

Poster Presentations

• Cross-Sectional Analysis of Demographic and Clinical Characteristics of Patients Using Icosapent Ethyl, With a Focus on Patients With Diabetes
  

Om P Ganda, Peter P Toth, Handrean Soran, et al...

- Available November 12th, 11:30-12:45 pm

- Zone 3, Science and Technology Hall, Level 2

• Eicosapentaenoic Acid Inhibits Lipoprotein(a) With Higher Rates of Oxidation Compared to Non-Modified Low-Density Lipoprotein In Vitro
  

Preston Mason, Samuel CR Sherratt, Peter Libby, et al…

– Available November 11th, 11:30-12:45 pm

- Zone 1, Science and Technology Hall, Level 2

• Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) have Competing Effects on Membrane Lipid Dynamics due to Differences in Structure
  Preston Mason, Samuel C.R. Sherratt, Sandeep Shrivastava, et al...                               – Available November 11th, 11:30-12:45 pm
  

- Zone 1, Science and Technology Hall, Level 2

About Amarin

Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our foundation in scientific research to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.